3H-pyrazolo[3,4-h]isoquinoline | 480419-16-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3H-pyrazolo[3,4-h]isoquinoline
• 英文别名: 3H-Pyrazolo[3,4-h]isoquinoline
• CAS: 480419-16-7
• 化学式: C₁₀H₇N₃
• mdl: MFCD18803267
• 分子量: 169.186
• InChiKey: PGUJOAOYKQFMHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3'-formyl-2'-methylacetanilide 在 硫酸 、 phosphorus pentoxide 、 溶剂黄146 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 2.0h， 生成 3H-pyrazolo[3,4-h]isoquinoline
  参考文献：
  名称：

  吡唑并异喹啉形成的合成研究

  摘要：

  7-氨基-5,8-二甲基-6-（苯硫基）异喹啉的重氮化意外地导致形成新的环系统，即3 H-吡唑并[3,4- h ]异喹啉作为其5-甲基-6-苯硫基衍生物。在这项工作中，母环系统及其5-甲基，6-溴-5-甲基和5-甲基-6-苯硫基衍生物被合成和表征。探索了转化的机制。

  DOI：

  10.1016/s0040-4020(02)00587-2

文献信息

• NITRILES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1724264A1

  公开（公告）日：2006-11-22

  The present invention relates to a compound of formula (I) wherein Y and Z each is independently N or C; ring A is a carbocyclic group or a heterocyclic group; ring B is a heterocyclic group containing at least one nitrogen atom; R is a hydrogen atom, a substituent, etc,; n is 0, or an integer of from 1 to 10, a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof. The compound of formula (I), a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof has an inhibitory activity against cysteine protease, and it is useful for the prophylaxis and/or treatment of a cysteine protease-related disease such as osteoporosis, etc.

  本发明涉及一种具有以下式（I）的化合物，其中Y和Z各自独立地为N或C；环A为碳环基团或杂环基团；环B为含有至少一个氮原子的杂环基团；R为氢原子、取代基等；n为0，或为1至10的整数，其盐、溶剂合物、N-氧化物或前药。具有式（I）的化合物，其盐、溶剂合物、N-氧化物或前药对半胱氨酸蛋白酶具有抑制活性，对于预防和/或治疗半胱氨酸蛋白酶相关疾病如骨质疏松症等是有用的。
• HETEROCYCLIC SPIRO COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1683797A1

  公开（公告）日：2006-07-26

  The compound represented by formula (I) (wherein D and G are cyclic group which may have a substituent(s) or alkyl which may have a substituent(s), W and Y are a bond or a spacer of which main chain has an atom number of 1-4, ringA and ringB are heterocyclic ring which may have a substituent(s), containing at least one carbon atom and one nitrogen atom and the ringA and ringB share one spiro carbon atom.), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof Since the compounds represented by formula (I), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof have the affinity to MBR, they are useful for the prevention and/or treatment for disease caused by stress.

  公式（I）所代表的化合物（其中D和G是可能具有取代基的环族，或者是可能具有取代基的烷基，W和Y是具有1-4个原子编号的主链的键或间隔物，环A和环B是可能具有取代基的杂环，含有至少一个碳原子和一个氮原子，环A和环B共享一个螺环碳原子），其盐，N-氧化物或溶剂合物，或其前药。由于公式（I）所代表的化合物，其盐，N-氧化物或溶剂合物，或其前药对MBR具有亲和力，因此它们对于预防和/或治疗由压力引起的疾病是有用的。
• Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
  申请人：Majid Nadeem Tahir

  公开号：US20050009859A1

  公开（公告）日：2005-01-13

  Compounds of the formula I are suitable for producing pharmaceuticals for the prophylaxis and therapy of diseases whose course involves an increased activity of NIK.

  公式I的化合物适用于制造用于预防和治疗疾病的药物，这些疾病的病程涉及NIK活性增加。
• [EN] PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES DE PYRAZOLOISOQUINOLINE UTILES COMME INHIBITEURS DE KINASE
  申请人：AVENTIS PHARMA INC

  公开号：WO2005012301A1

  公开（公告）日：2005-02-10

  Novel pyrazoloisoquinoline derivatives as kinase inhibitors are disclosed which are suitable for producing pharmaceuticals for the prophylaxis and therapy of diseases whose course involves an increased activity of NIK.

  揭示了作为激酶抑制剂的新型吡唑异喹啉衍生物，适用于生产用于预防和治疗涉及NIK增强活性的疾病的药物。
• Pyrazolo-pyridine derivatives as ligands for gaba receptors
  申请人：——

  公开号：US20030004180A1

  公开（公告）日：2003-01-02

  A class of substituted and/or ring-fused pyrazolo[3,4-b]pyridine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent on the pyrazole nitrogen atom adjacent the pyridine nucleus, and an optionally substituted cycloalkyl-alkoxy, aryl-alkoxy or heteroaryl-alkoxy substituent on the carbon atom adjacent the pyridine ring nitrogen atom, are selective ligands for GABA A receptors, in particular having high affinity for the &bgr;2 and/or &bgr;3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of adverse neurological disorders, including anxiety and convulsions.

  一类取代和/或环融合的吡唑并[3,4-b]吡啶衍生物，其在吡啶环上邻近吡唑氮原子处具有可选的取代环烷基、苯基或杂环基取代基，并在邻近吡啶环氮原子的碳原子上具有可选的取代环烷氧基、芳基氧基或杂环基氧基取代基，是GABAA受体的选择性配体，特别是具有高亲和力的β2和/或β3亚单位，因此对于治疗和/或预防不良神经疾病，包括焦虑和惊厥，具有益处。